Heron Inc

HRTX NASDAQ
18.45
-0.75
-3.91%
盘后: 18.40 -0.05 -0.27% 19:34 07/19 EDT
开盘
19.19
昨收
19.20
最高
19.22
最低
18.42
成交量
57.99万
成交均量(3M)
113.59万
52周最高
41.55
52周最低
16.20
换手率
0.73%
市值
14.61亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Heron Inc HRTX股票价格,Heron Inc股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
展开 >

最近浏览

名称
价格
涨跌幅